The Joaquim Ferreira Lab aims to contribute to the development of effective and safe therapeutic interventions through the establishment of optimized methodologies for the design, conduction, analysis and report of clinical trials.
The main clinical models for our research are the neurodegenerative diseases (mainly Parkinson's Disease and Huntington's Disease), neglected patient populations (e.g. paediatric, rare diseases, late stage populations) and "orphan" interventions (e.g. rehabilitation, non‐pharmacological and non‐surgical interventions).
The main clinical pharmacology domains of interest are clinical trials methodology, outcomes, systematic reviews, safety and drug utilization.
1. To develop new methodologies for the design of exploratory studies and the evaluation of biomarkers as measures of drug action in clinical trials.
2. To facilitate the 'translational' research component related to the design and conduct of the early phase of drug studies in humans.
3. To support the Clinical Research Centre of the Lisbon Medical Academic Centre (CIC‐CAML) in all aspects related with drug development studies. The decision to create the CIC‐CAML as a facility unit for clinical and translational research was done recently and the infrastructures for the centre are now being implemented. CIC‐CAML will favor the design and conduct of early phase clinical trials and proof of concept studies. The CIC‐CAML has unique clinical and translational capacities to become a top‐level European clinical research centre with innovative investigator‐initiated projects, active collaborations with international networks and partnerships with industry with a scope extending throughout the translational continuum. At the current stage, compounds being developed or studied at the iMM Units have reached a clinical stage and the first trials in patients are being designed and will start later this year. Some of the first exploratory trials will be conducted in the CHLN with the support of the CIC CAML.
4. To organize and provide comprehensive clinical pharmacology services to other iMM research groups and professionals in academia.
5. To educate and train in clinical trials methodology and Good Clinical Practice.
6. To foster investigator‐initiated trials.
7. To foster collaborations with industry.
Ana Teresa Santos
Carla Leão Guerreiro
Catarina Severiano e Sousa
Clinical Staff Scientist
João Simões Santos
Leonor Correia Guedes
Maria João Forjaz
Mário Miguel Rosa
Language Area Coordinatorrafaela.firstname.lastname@example.org
Ricardo M Fernandes
Solange Carolino Alves
Vanda Freitas Castro
Verónica C. Caniça
- Clinical Pharmacology
- Movement Disorders
- Parkinson's Disease
- Huntington's Disease
- Botulinum Toxin
- Clinical Trials
- Systematic Reviews
Ongoing Research Projects
2014 JPND funded project COURAGE-PD COmprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease
2014 JPND funded project CLaSP: Care for Late Stage Parkinsonism
2013 Imaging of Basal Ganglia from Magnetic Induction Tomography, supported by Foundation for Science and Technology
2013 Glucocerebrosidase in Parkinson's disease: from risk factor to biomarker supported by Foundation for Science and Technology
2012 FP7 funded project SENSE-PARK (2012-2015): Supporting and Empowering Parkinson patients in their home environment using a Novel Sensory information system that monitors daily life-relevant parameters of Parkinson disease and their change.
2010 Epidemiological study to assess the prevalence of Parkinson's disease in Portugal. Promoted by the Portuguese Association of Parkinson's Disease Patients and sponsored by Regional Directors of Health
2008/2011 Slow and Rapid Progression Parkinson´s Disease: Molecular Determinants and Biomarkers, Foundation for Science and Technology. Principal Investigator: Tiago Outeiro. PIC/IC/82760/2007
- Joaquim Ferreira, Caixa Geral de Depósitos Science Honor Prize 2015.
- Joaquim Ferreira, Caixa Geral de Depósitos Science Award 2016.
- Daniel Caldeira, Bolsa de Interno-Doutorando pela Fundação para a Ciência e Tecnologia (FCT) SFRH/SINTD/96409/2013 (2013).
- Daniel Caldeira, Melhor poster na sessão “Health technology assessment in cardiovascular disease", promovido pelo CUTEheart, no XXXVII Congresso Português de Cardiologia 2016.
- Daniel Caldeira, Distinguido em Janeiro de 2017 pela Revista Portuguesa de Factores de Risco como autor do artigo publicado em 2014, mais lido em formato digital “Café e hipertensão arterial: um dilema?”.